Good News for Cannabis Operators
— And the Catch Nobody's Mentioning

Here's the cannabis rescheduling update most coverage is leaving out: the medical relief is real, but a court case, an unconfirmed DEA timeline, and an insurance wrinkle complicate it.

What's Actually True Right Now

State-licensed medical cannabis operators have a genuine, statute-grounded reason to feel good about this year. Since the Acting Attorney General's April 2026 order moved state-licensed medical marijuana and FDA-approved cannabinoid products into Schedule III, Section 280E no longer applies to that slice of a qualifying medical operator's business, starting with the 2026 tax year. That is not a preview or a proposal. It is the current, operative rule for a license holder who qualifies.

Adult-use product stayed exactly where it was. Schedule I, fully subject to 280E, no change at all. For most of the industry, that is most of the revenue. California alone runs overwhelmingly adult-use, and that side of the business pays 280E in full regardless of what happened this spring.

The Catch Nobody's Mentioning

The bigger catch is legal, not regulatory. The same April order that delivered the medical relief is being challenged right now in the D.C. Circuit Court of Appeals, in a case that has gotten far less attention than the DEA hearing. Petitioners, including a physician drug-testing trade association and a pharmaceutical company pursuing its own FDA approval for a cannabis-derived drug, argue the Attorney General exceeded his authority and skipped rulemaking procedures the law required. As of this writing, the court has not ruled on the merits. It is still deciding whether the petitioners even have standing to sue, and whether the rescheduling order should be paused while the case proceeds. If the court grants both, the medical relief operators are currently relying on could be put on hold while the litigation plays out.

None of this means the relief is not real today. It means real today and certain to still be true in six months are two different things, and any plan built on the assumption of permanence is standing on ground that is still being argued in court.

The Timeline Nobody Should Trust

The separate DEA hearing on rescheduling marijuana more broadly, moving the rest of the market out of Schedule I, wrapped on July 15 after weeks of testimony. Post-hearing briefs are due August 17. After that, the presiding administrative law judge writes a recommendation, with no announced timeline, and the DEA Administrator makes the final call, also with no announced timeline. Nobody, not the agency, not the judge, not the trade press, has confirmed a decision this fall. Anyone telling you a ruling is coming by a specific date is guessing.

What Doesn't Depend on Any of This

Here is what does not wait on any court, hearing, or agency: the cost structure underneath your insurance program. A captive insurance company lets a cannabis business retain the premium it is already paying and build equity from disciplined risk management, regardless of what schedule marijuana sits in on any given day. It does not require a ruling. It does not require winning at the D.C. Circuit. It is available now, priced against your own claims history instead of a commercial market that has spent years pricing cannabis risk defensively.

As a general guideline, this tends to make the most economic sense above roughly $200,000 in annual premium for cannabis operators specifically, though that threshold can run lower depending on your loss experience. Section 280E itself is a federal rule, enforced by the IRS, not a state one. Whether it also touches your state tax bill depends on your state's own conformity rules. California, for example, decouples from 280E for licensed cannabis businesses, so it does not add to the state-tax side of the equation there. What can still push the threshold lower is the separate layer of cannabis-specific excise, cultivation, or gross-receipts taxes your state or municipality charges on top, regardless of how it treats 280E.

There's a related wrinkle worth naming directly, since it splits this post's own audience. Whether your insurance premium is deductible at all under 280E depends on what kind of cannabis business you run. General liability, D&O, and employment practices coverage are treated as disallowed overhead for any plant-touching operator. A cultivator or processor can often capitalize insurance tied to the production facility or the crop itself into cost of goods sold, the same bucket rent and utilities go into, and get some tax benefit that way. A dispensary with no production side gets none of that: under longstanding IRS guidance, a pure reseller can only add invoice price and freight-in to cost of goods sold, so its insurance premium is fully non-deductible no matter who the policy is written through.

That doesn't weaken the case for a captive. It strengthens it. Whether the premium goes to a commercial carrier or your own captive, its deductibility is identical either way, a disallowed dollar stays disallowed regardless of who insures you. What changes is what happens to that dollar after it's paid. Paid to a commercial carrier, a low-claims year becomes their profit. Paid to a captive, it becomes equity you keep. If you're already paying with fully after-tax dollars, that's a bigger reason to want the money back, not a smaller one.

What This Means for How You Plan

• Treat the current 280E relief as real, but conditional. Plan around it for the 2026 tax year, and build in a contingency for what changes if the D.C. Circuit stays the underlying order.
• Don't build a timeline around "this fall." No agency has confirmed one. Base decisions on the actual filing deadlines, like the post-hearing briefs due August 17, rather than a guess about what comes after.
• Know your own deductibility position before you compare premiums. A cultivator capitalizing facility and crop insurance into COGS is in a different spot than a dispensary that can't touch COGS at all. Either way, a captive turns your premium into equity instead of a stranger's profit.
• Fix what you control before the rest resolves. A captive doesn't wait on any of these processes, and operators who start now won't be the ones scrambling to react to whatever the D.C. Circuit or the DEA eventually decides.

Contact 3F Captive Services for a no-cost policy analysis of your cannabis operation's insurance structure. That analysis will show you where you're covered, where you aren't (often the biggest surprise), and where you should be concerned.

This post is for informational purposes only and does not constitute insurance, legal, or tax advice. Rescheduling status, 280E treatment, state tax conformity, COGS treatment, and captive insurance structures vary by license type, jurisdiction, and individual circumstances. Consult qualified legal, tax, and insurance advisors regarding your specific situation.

Sources

1. U.S. Department of Justice, Final Order, 91 Fed. Reg. 22714 (Apr. 28, 2026), rescheduling state-licensed medical marijuana and FDA-approved cannabinoid products to Schedule III.

2. U.S. Court of Appeals for the District of Columbia Circuit, MMJ BioPharma Cultivation, et al. v. U.S. Department of Justice, Docket No. 26-1136, briefing on standing and motion to stay.

3. Harris Sliwoski LLP, “Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test,” Canna Law Blog, July 24, 2026.

4. DEA Administrative Law Judge Derek Julius, hearing schedule order concluding proceedings July 15, 2026; post-hearing briefs due August 17, 2026.

5. Shay Aaron Gilmore, “Cannabis 280E Relief: Who Keeps the $1.6 Billion?”, June 29, 2026.

6. Internal Revenue Service, “Cannabis industry,” irs.gov, on Section 280E as a federal-only limitation.

7. California Franchise Tax Board, “Cannabis Industry,” ftb.ca.gov, on California's decoupling from 280E for licensed cannabis businesses under AB 37 (2019).

8. Internal Revenue Service, Chief Counsel Advice 201504011 (Jan. 23, 2015), holding that 280E taxpayers compute cost of goods sold under the pre-1986 § 471 regulations, not the broader post-1986 § 263A capitalization rules.

9. Treas. Reg. § 1.471-11(b), (c)(2)(i); Internal Revenue Service, “Cannabis Industry Frequently Asked Questions,” irs.gov, last reviewed April 26, 2026, confirming COGS is computed under Section 471.

‍